A detailed history of First Horizon Advisors, Inc. transactions in Genmab A/S stock. As of the latest transaction made, First Horizon Advisors, Inc. holds 811 shares of GMAB stock, worth $16,236. This represents 0.0% of its overall portfolio holdings.

Number of Shares
811
Previous 829 2.17%
Holding current value
$16,236
Previous $20,000 5.0%
% of portfolio
0.0%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$23.84 - $28.48 $429 - $512
-18 Reduced 2.17%
811 $19,000
Q1 2024

Apr 26, 2024

SELL
$26.43 - $32.77 $4,889 - $6,062
-185 Reduced 18.24%
829 $24,000
Q4 2023

Feb 06, 2024

SELL
$27.94 - $35.44 $3,157 - $4,004
-113 Reduced 10.03%
1,014 $32,000
Q3 2023

Oct 27, 2023

BUY
$35.27 - $42.24 $32,413 - $38,818
919 Added 441.83%
1,127 $39,000
Q2 2023

Aug 03, 2023

BUY
$37.4 - $42.94 $3,403 - $3,907
91 Added 77.78%
208 $7,000
Q1 2023

May 15, 2023

SELL
$34.88 - $43.22 $3,592 - $4,451
-103 Reduced 46.82%
117 $4,000
Q4 2022

Feb 10, 2023

BUY
$33.8 - $47.06 $1,622 - $2,258
48 Added 27.91%
220 $9,000
Q3 2022

Nov 09, 2022

SELL
$31.52 - $373.61 $9,865 - $116,939
-313 Reduced 64.54%
172 $5,000
Q2 2022

Aug 02, 2022

SELL
$26.83 - $38.57 $29,647 - $42,619
-1,105 Reduced 69.5%
485 $15,000
Q1 2022

May 10, 2022

BUY
$30.95 - $39.68 $5,075 - $6,507
164 Added 11.5%
1,590 $58,000
Q4 2021

Feb 09, 2022

BUY
$35.87 - $47.12 $502 - $659
14 Added 0.99%
1,426 $56,000
Q3 2021

Nov 15, 2021

SELL
$41.55 - $48.72 $4,653 - $5,456
-112 Reduced 7.35%
1,412 $61,000
Q3 2021

Nov 09, 2021

BUY
$41.55 - $48.72 $61,826 - $72,495
1,488 Added 4133.33%
1,524 $66,000
Q2 2021

Aug 09, 2021

BUY
$32.88 - $44.57 $1,183 - $1,604
36 New
36 $1,000
Q4 2020

Feb 11, 2021

SELL
$33.66 - $40.76 $807 - $978
-24 Closed
0 $0
Q3 2020

Nov 12, 2020

SELL
$33.07 - $38.68 $18,916 - $22,124
-572 Reduced 95.97%
24 $0
Q1 2020

May 05, 2020

BUY
$17.15 - $25.22 $10,221 - $15,031
596 New
596 $12,000

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $13.2B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track First Horizon Advisors, Inc. Portfolio

Follow First Horizon Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Horizon Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Horizon Advisors, Inc. with notifications on news.